Skip to main content
SpringerLink
Log in

Growth Factor Antagonists in Prostatic Cancer: Suramin and Cytotoxic Polyamines as Potential Therapy

  • Chapter
Book cover Molecular and Cellular Biology of Prostate Cancer

  • 91 Accesses

Abstract

Prostatic Cancer is the leading site for cancer in men over 50 years of age and is the second leading cause of cancer deaths in the US (1). Clinically manifest prostatic cancer is more common in the US than in Japan while the incidence of latent cancer is similar between the two countries. The incidence of prostatic cancer of first generation males of Japanese living in the US is the same as that of US males. The implication is that life style differences are important for the progression of the disease. As prostatic cancer is refractory to most standard chemotherapeutic agents and hormone therapy is only palliative it may be that it will be easier to prevent the progression of prostatic cancer than to cure it. Consideration should be given to 3 omega unsaturated fatty acids, which are common in fish oils, as possible agents in a study of prevention of progression. The 3 omega unsaturated fatty acids have proven beneficial in the prevention of cancer and reduced the growth of prostatic cancer in nude mice (2,3). Other cultural differences in nutrition such as the use of green tea should be investigated to identify other potential anti-tumor progression factors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Silverburg, E., and Lubera, J.A. Cancer Statistics, CA 39:3–22, 1989.

    Google Scholar 

  2. Telang, N.T., Basu, A., Kurihara, H., Osborne, M.P. and Modak, M.J. Modulation in the expression of murine mammary tumor virus, ras proto-oncogene and of alveolar hyperplasia by fatty acids in mouse mammary explant cultures. Anticancer Res., 8:971–976, 1988.

    PubMed  CAS  Google Scholar 

  3. Karmali, R.A., Reichel, P., Cohen, L.A., Terano, T., Hirai, A., Tamura, Y. and Yoshida, S. The effects of dietary omega-3 fatty acids on the DU-145 transplantable human prostatic tumor. Anticancer Res., 7:1173–1180, 1987.

    PubMed  CAS  Google Scholar 

  4. Raina, A., Pajula, R., Eloranta, T. A rapid assay for spermidine and spermine synthesis: distribution of polyamine synthesizing enzymes and methionine adenosyltransferase in rat tissues. FEBS Lett., 76:252–256, 1976.

    Article  Google Scholar 

  5. Pegg, A.E., Lockwood, D.H. and Williams-Ashman, H.G. Concentrations of polyamines and their enzymic synthesis during androgen-induced prostatic growth. Biochem. J., 117:17–31, 1970.

    PubMed  CAS  Google Scholar 

  6. Heston, W.D.W., Kadmon, D. and Fair, W.R Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor α-DFMO. The Prostate, 3:383–389, 1982.

    Article  PubMed  CAS  Google Scholar 

  7. Tabor, C.W. and Tabor, H. Polyamines. Ann. Rev. Biochem., 53:740–790, 1984.

    Article  Google Scholar 

  8. Pegg, A.E. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res., 48:759–774, 1988.

    PubMed  CAS  Google Scholar 

  9. Porter, C.W. and Sufrin, J.R Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential chemotherapeutic strategy. Anticancer Res., 6:535–535, 1986.

    Google Scholar 

  10. Seppanen P., Alhonen-Hongisto, L. and Janne, J. Death of tumor cells in response to the use of a stimulated polyamine uptake for the transport of MGBG. Eur. J. Biochem., 18:571–576, 1981.

    Article  Google Scholar 

  11. Herr, H.W., Kleinert, E.L., Relyea, N.M. and Whitmore, W.F. Jr. Potentiation of MGBG by DFMO in rat prostate. Cancer, 53:1294–1296, 1984.

    Article  PubMed  CAS  Google Scholar 

  12. Romijin, J.C., Van Steenbruge, G.J. and Schroeder, F.H. Effects of polyamine antimetabolites in the growth rate of human prostatic tumors transplantable into nude mice. Fouth int. workshop on immune deficient animals. (Karger, Basel) pp. 370, 1984.

    Google Scholar 

  13. Persson, L., Holm, I., Asle, A. and Heby, O. Curative effect of DFMO on mice bearing mutant L1210 leukemia cells deficient in polyamine uptake. Cancer Res., 48:4807–4811, 1988.

    PubMed  CAS  Google Scholar 

  14. Kadmon, D. and Heston, W.D.W. Manuscript in preparation.

    Google Scholar 

  15. Heston, W.D.W., Kadmon, D., Covey, D.F. and Fair, W.R Differential effect of DFMO on the in vivo uptake of 14C-labeled polyamines and MGBG by a prostate derived tumor. Cancer Res., 44:1034–1040, 1984.

    PubMed  CAS  Google Scholar 

  16. Heston, W.D.W., Yang, C-R., Pliner, L., Russo, P. and Covey, D.F. Cytotoxic activity of a polyamine analog, monoaziridinyl putrescine, against the PC-3 human prostatic carcinoma cell line. Cancer Res., 47:3627–3631, 1987.

    PubMed  CAS  Google Scholar 

  17. Welch, M.J., Coleman, R.E., Straatman, M.G., Asberry, B.E., Primeau, J.L., Fair, W.R. and Ter-Pergossian, M.-M. C11-labeled methylated polyamine analogs: uptake in prostate and tumor in animal models. J. Nuel. Med., 18:74–78, 1977.

    CAS  Google Scholar 

  18. Kadmon, D., Welsh, M.J., and personal communication.

    Google Scholar 

  19. Bergeron, R.J. Methods for the selective modification of spermidine and its homologs. Acc. Chem. Res., 19:105–113, 1986.

    Article  CAS  Google Scholar 

  20. Bergeron, R.J., Hawthorne, T.R., Vinson, J.R.T., Beck, D.F. Jr. and Igeno, M.J. Role of the methylene backbone in the antiproliferative activity of polyamine analogs on L1210 cells. Cancer Res., 49:2959–2964, 1989.

    PubMed  CAS  Google Scholar 

  21. Schuber, F. Influence of polyamines on membrane functions. Biochem. J., 260:1–10, 1989.

    PubMed  CAS  Google Scholar 

  22. Marton, L.J. Effects of treatment with DNA-directed cancer chemotherapeutic agents after polyamine depletion. Pharmacol. Ther., 32:183–190, 1987.

    Article  PubMed  CAS  Google Scholar 

  23. Scher, H., Yagoda, A., Ahmed, T., et al. Phase II trial of mitoguazone in patients with hormone resistant adenocarcinoma of the prostate. J. Clin. Oncol., 3:224–229, 1989.

    Google Scholar 

  24. Story, M.T., Sassa, J., Jacobs, S.C. and Lawson, R.K Prostatic growth factor: purification and structural relationship to basic fibroblast growth factor. Biochem., 26:3843–3849, 1987.

    Article  CAS  Google Scholar 

  25. Matuo, Y., Nishi, N. and Wada, F. Growth factors in the prostate. Arch. Androl., 19:193–210, 1987.

    Article  PubMed  CAS  Google Scholar 

  26. Matuo, Y., Nishi Matsui, S., Sandberg, A.A., Issacs, J.T. and Wada, F. Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. Cancer Res., 47:188–192, 1987.

    PubMed  CAS  Google Scholar 

  27. Mannson, P.F., Adams, P., Kan, M. and McKeehan W.L. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res., 49:1485–1494, 1989.

    Google Scholar 

  28. Mydlo, J.H., Bulbul, M.A., Richon, V.M., Heston, W.D.W. and Fair, W.R. Heparin-binding growth factor isolated from human prostatic extracts. The Prostate, 12:343–355, 1988.

    Article  PubMed  CAS  Google Scholar 

  29. Mydlo, J.H., Michaeli, J., Heston, W.D.W. and Fair, W.R. Expression of basic fibroblast growth factor mRNA in BPH and prostatic carcinoma. The Prostate, 13:241–247, 1988.

    Article  PubMed  CAS  Google Scholar 

  30. Smith, E.P., Russell, W.E., French, F.S. and Wilson, E.M. A form of basic FGF is secreted into the adluminal fluid of the rat coagulating gland (anterior prostate). The Prostate, 14:353–365, 1989.

    Article  PubMed  CAS  Google Scholar 

  31. Nishi, N., Matuo, Y., Kuritomi, K., Takenaka, I., Usami, M., Kotake, T. and Wada, F: Comparative analysis of growth factors in normal and pathologic human prostates. The Prostate, 13:39–48, 1988.

    Article  PubMed  CAS  Google Scholar 

  32. Coffey, R.J., Leoff, E.B., Shipley, G.D, and Moses, H.L. Suramin inhibition of growth factor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol., 132:143–148, 1987.

    Article  PubMed  CAS  Google Scholar 

  33. Stein, C.A., LaRocca, R.V., McAtee, T.R. and Myers, C.E. Suramin an anticancer drug with a unique mechanism of action. J. Clin. Oncol., 7:499–508, 1989.

    PubMed  CAS  Google Scholar 

  34. Myers, C.E. Presentation at MSKCC.

    Google Scholar 

  35. Finch, P.W., Rubin, J.S., Miki T., Ron, D. and Aaronson, S.A. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science, 245:752–755, 1989.

    Article  PubMed  CAS  Google Scholar 

  36. Chang, S-M. and Chung, L.W.K Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen. Endocrinol., 125:2719–2727, 1989.

    Article  CAS  Google Scholar 

  37. Chackal-Roy, M., Niemeyer, C., Moore, M. and Zetter, B.R. Stimulation human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest., 84:43–50, 1989.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Oncology Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Warren D. W. Heston

Authors
  1. Warren D. W. Heston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Office of Scientific Administration, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA

    James P. Karr Ph.D. (Chief) (Chief)

  2. The Johns Hopkins Hospital and University, Marburg Building, 600 North Wolfe Street, Baltimore, MD, 21205, USA

    Donald S. Coffey Ph.D. (Professor of Urology, Oncology and Pharmacology) (Professor of Urology, Oncology and Pharmacology)

  3. Department of Growth Biochemistry and Physiology, Merck, Sharpe and Dohme Research Lab, 126 East Lincoln Avenue, Rahway, NJ, 07065, USA

    Roy G. Smith Ph.D.

  4. Mayo Clinic, Guggenheim-4 200 First Street, SW, Rochester, MN, 55905, USA

    Donald J. Tindall Ph.D. (Professor of Urologic Research) (Professor of Urologic Research)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Heston, W.D.W. (1991). Growth Factor Antagonists in Prostatic Cancer: Suramin and Cytotoxic Polyamines as Potential Therapy. In: Karr, J.P., Coffey, D.S., Smith, R.G., Tindall, D.J. (eds) Molecular and Cellular Biology of Prostate Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3704-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3704-5_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6647-8

  • Online ISBN: 978-1-4615-3704-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation